Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Shutterstock/PhotobyTawat

US to begin rollout of Pfizer/BioNTech vaccine as the country's death toll nears 300,000

It is the first Covid-19 vaccine approved in the US.

LAST UPDATE | 12 Dec 2020

OFFICIALS IN THE US say the nation’s first coronavirus vaccine will begin arriving across the country on Monday morning.

Shipping companies UPS and FedEx will deliver Pfizer’s vaccine to nearly 150 state locations, while another 450 sites will get the vaccine on Tuesday and Wednesday.

Army General Gustave Perna, part of the Trump administration’s vaccine development programme Operation Warp Speed, said health workers will receive the jab first before then administering it to others.

The locations include hospitals and other sites able to meet the ultra-cold storage requirements for the vaccine. Within three weeks, vaccines should be delivered to local pharmacies and other locations, Perna added.

The announcement kicks off a massive logistical operation involving the federal and state governments, private companies and health workers to quickly distribute limited vaccine supplies throughout the US.

Initially, about three million doses are expected to be shipped nationwide. A similar amount is to be held in reserve for those recipients’ second dose.

Initial shipments are expected to leave Pfizer’s manufacturing plant in Kalamazoo, Michigan, by lorry and then be flown to regional hubs around the country.

Adding to the distribution challenge is the fact the vaccine must be stored and shipped at ultra-low temperatures. Pfizer has developed shipping containers that use dry ice, and GPS-enabled sensors will allow the company to track each shipment and ensure it stays cold.

The announcement was made after the US gave the final go-ahead yesterday evening to approve the Pfizer/BioNTech Covid-19 vaccine.

It came hours after White House chief of staff Mark Meadows pressed FDA chief Stephen Hahn to grant an emergency use authorisation for Pfizer’s vaccine by the end of the day or face possible firing, according to two administration officials.

Meadows spoke to Dr Hahn by telephone on Friday and told him his job was in jeopardy if the emergency use authorisation was not issued before Saturday, according to a senior Trump administration official who spoke to The Associated Press on condition of anonymity.

The ultimatum is understood to have come at President Donald Trump’s direction.

The threat marked the latest attempt by the Trump administration to override government scientists working to combat the deadly pandemic.

Even with an FDA decision expected within hours, Trump and his deputies proved unwilling to let regulators work through their careful review, which includes drafting safety warning labels and instructions for physicians.

Dr Hahn disputed as “untrue” these characterisations of his conversation with Meadows.

But Trump tweeted directly at Dr Hahn earlier on Friday, complaining that the FDA “is still a big, old, slow turtle”. Trump has publicly lambasted the pace of the FDA’s vaccine review process.

“Get the dam vaccines out NOW, Dr. Hahn,” Trump tweeted.

“Stop playing games and start saving lives.”

Initial doses of the approved vaccine in the US are scarce and rationed as the country joins Britain and several other nations in scrambling to vaccinate as many people as possible ahead of a long, grim winter.

It will take months of work to tamp down the coronavirus that has surged to catastrophic levels in recent weeks and already claimed 1.5 million lives globally.

The move sets off what will be the largest vaccination campaign in US history – but it also has global ramifications as a role model to many other countries facing the same decision.

It offers the ability “in this situation where the pandemic is out of control, to bring hope to the people”, Dr Ugur Sahin, the CEO of BioNTech, told The Associated Press.

The world desperately needs multiple vaccines for enough to go around, and the Pfizer-BioNTech shot is the first based on rigorous scientific testing to emerge from that worldwide race – a record-setting scientific achievement that shaved years off the usual process.

“I don’t think you would have found a scientist on this planet that would have predicted this 11 months ago,” said Dr Paul Offit, a vaccine expert at Children’s Hospital of Philadelphia who advises the FDA.

Another vaccine

The US is considering a second vaccine, made by Moderna, that could roll out in another week. In early January, Johnson & Johnson expects to learn if its vaccine is working in final testing.

Europe is set to make its own decision on the Pfizer-BioNTech and Moderna shots later this month, an important step as some other candidates that multiple countries were anxiously awaiting have hit roadblocks.

On Friday, Sanofi and GSK announced a months-long delay after early tests showed their vaccine did not work well enough in older adults.

Both China and Russia did not wait for final-stage tests before beginning vaccinations with some homegrown shots.

Trump said late on Friday that Pfizer had “passed the gold standard of safety” in a video statement hailing the vaccine as “one of the greatest scientific accomplishments in history”.

Some three million doses of the Pfizer-BioNTech vaccine are expected in the first shipments around the country, according to officials with Operation Warp Speed, the Trump administration’s vaccine development program.

A similar amount is to be held in reserve for those recipients’ second dose.

The government is still deciding final recommendations, but expected to follow health workers and nursing homes are other essential workers, older adults and people at high risk because of other health problems.

US authorities do not expect enough for the general population before spring, and that is assuming there are no manufacturing glitches.

Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.

Author
Nora Creamer
View 8 comments
Close
8 Comments
This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
Leave a Comment
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.

    Leave a commentcancel

     
    JournalTv
    News in 60 seconds